Cassava Sciences, Inc., a clinical-stage drug development company, develops drugs for nervous system disorders. The company's lead therapeutic product candidate PTI-125, a small molecule drug that is in Phase II clinical trial for the treatment of Alzheimer's disease. It is also developing PTI-125Dx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [01/16/2020 10:10 PST] Cassava Sciences, Inc. (:SAVA), Up By 100.00% ($7.65) From $7.654 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [01/16/2020 07:44 PST] SAVA Expected to Trade Up Short Term
• [01/13/2020 10:10 PST] Cassava Sciences, Inc. (:SAVA), Down By 100.00% ($8.45) From $8.453 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [01/13/2020 07:53 PST] SAVA Expected to Trade Down After Bearish Patterns Develop
• [01/06/2020 10:10 PST] Cassava Sciences, Inc. (:SAVA), Up By 100.00% ($8.68) From $8.675 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [01/06/2020 07:36 PST] SAVA Expected to Trade Up After Bullish Patterns Develop
• [01/02/2020 10:10 PST] Cassava Sciences, Inc. (:SAVA), Up By 100.00% ($6.42) From $6.420 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [12/31/2019 07:45 PST] SAVA Expected to Trade Up After Bullish Patterns Develop
• [12/26/2019 10:10 PST] Cassava Sciences, Inc. (:SAVA), Up By 100.00% ($4.46) From $4.455 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [12/26/2019 07:37 PST] SAVA Expected to Trade Up After Bullish Patterns Develop